Literature DB >> 11431670

Is the dyspnea during adenosine cardiac stress test caused by bronchospasm?

K K Balan1, M Critchley.   

Abstract

BACKGROUND: Adenosine cardiac stress is widely used as an alternative to exercise testing during myocardial perfusion imaging (MPI). Dyspnea often accompanies the adenosine stress test. Although known asthmatic patients are excluded from this test because of the danger of bronchospasm, there is incomplete information regarding the role of factors such as chronic obstructive pulmonary disease (COPD) and tobacco smoking in adenosine-induced dyspnea. PATIENTS AND METHODS: A total of 122 consecutive patients (75 male, 47 female; mean age 59 years, SD 10 years) undergoing pharmacologic stress testing with an intravenous infusion of adenosine also had volume-flow spirometry (Vitalograph Compact, Vitalograph Ltd) before, during, and after the test. The indices assessed were forced expiratory volume in one second, its ratio to the forced vital capacity, and peak expiratory flow rate.
RESULTS: Mild to severe symptoms were experienced by 81% of patients during adenosine infusion. More than half the patients had dyspnea, but there was no associated bronchospasm. Although the patients with COPD showed parameters indicative of bronchial resistance compared with those without this problem, there was no further deterioration after adenosine infusion. Similarly, patients with a history of tobacco abuse, despite showing a tendency toward increasing airways resistance, had no bronchospasm during the administration of adenosine.
CONCLUSIONS: (1) Although dyspnea is a common problem during adenosine stress MPI, it is not associated with any appreciable bronchospasm. (2) COPD and tobacco abuse do not appear to be contraindications to adenosine stress MPI studies. However, it is probably safe to exclude patients with severe COPD from adenosine stress MPI until after further evaluation with larger numbers of patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11431670     DOI: 10.1067/mhj.2001.116070

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  10 in total

1.  Hemodynamic response, arrhythmic risk, and overall safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic obstructive pulmonary disease and bronchial asthma patients.

Authors:  Zehra Husain; Gurunanthan Palani; Rafael Cabrera; Aarthee S Karthikeyan; Sunitha Dhanalakota; Suba Pathmanathan; Gordon Jacobsen; Karthik Ananthasubramaniam
Journal:  Int J Cardiovasc Imaging       Date:  2011-12-27       Impact factor: 2.357

2.  Lessons from regadenoson and low-level treadmill/regadenoson myocardial perfusion imaging: initial clinical experience in 1263 patients.

Authors:  Deborah H Kwon; Manuel D Cerqueira; Ron Young; Penny Houghtaling; Elizabeth Lieber; Venu Menon; Richard C Brunken; Wael A Jaber
Journal:  J Nucl Cardiol       Date:  2010-04-23       Impact factor: 5.952

Review 3.  Cardiac disease in chronic obstructive pulmonary disease.

Authors:  Jeremy A Falk; Steven Kadiev; Gerard J Criner; Steven M Scharf; Omar A Minai; Philip Diaz
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

4.  Side effect profile and tolerability of adenosine myocardial perfusion scintigraphy in patients with mild asthma or chronic obstructive pulmonary disease.

Authors:  Eliana Reyes; Chee Y Loong; Kshama Wechalekar; Katherine Latus; Constantinos Anagnostopoulos; S Richard Underwood
Journal:  J Nucl Cardiol       Date:  2007-10-18       Impact factor: 5.952

5.  Tolerance and safety of adenosine stress perfusion cardiovascular magnetic resonance imaging in patients with severe coronary artery disease.

Authors:  Theodoros D Karamitsos; Jayanth R Arnold; Tammy J Pegg; Adrian S H Cheng; William J van Gaal; Jane M Francis; Adrian P Banning; Stefan Neubauer; Joseph B Selvanayagam
Journal:  Int J Cardiovasc Imaging       Date:  2008-11-27       Impact factor: 2.357

6.  Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial.

Authors:  Brian R Leaker; B O'Connor; Trevor T Hansel; Peter J Barnes; Lixen Meng; Vandana S Mathur; Hsiao D Lieu
Journal:  J Nucl Cardiol       Date:  2008-04-14       Impact factor: 5.952

7.  Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled trial (RegCOPD trial).

Authors:  Gregory S Thomas; Bruce R Tammelin; George L Schiffman; Rudy Marquez; Deborah L Rice; Douglas Milikien; Vandana Mathur
Journal:  J Nucl Cardiol       Date:  2008-04-14       Impact factor: 5.952

8.  Respiratory resistance of patients during cardiac stress testing with adenosine: is dyspnea a sign of bronchospasm?

Authors:  Eva Fricke; Elke Esdorn; Annett Kammeier; Harald Fricke; Rainer Preuss; Wolfgang Burchert; Oliver Lindner
Journal:  J Nucl Cardiol       Date:  2008 Jan-Feb       Impact factor: 5.952

9.  Prognosis in patients having chronic obstructive pulmonary disease with significant coronary artery lesion angina.

Authors:  Tae Yun Park; Kyung Hee Kim; Hyun Kyoung Koo; Ji Yeon Lee; Sang-Min Lee; Jae-Jun Yim; Chul-Gyu Yoo; Young Whan Kim; Sung Koo Han; Seok-Chul Yang
Journal:  Korean J Intern Med       Date:  2012-05-31       Impact factor: 2.884

10.  The pulmonary effects of intravenous adenosine in asthmatic subjects.

Authors:  Nausherwan K Burki; Mahmud Alam; Lu-Yuan Lee
Journal:  Respir Res       Date:  2006-11-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.